门冬胰岛素辅助地特胰岛素治疗妊娠期糖尿病患者的临床疗效

doi:10.3969/j.issn.1671-7171.2026.06.023

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1249 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】 To explore the clinical efficacy of insulin aspart combined with insulin detemir in the treatment of patients with gestational diabetes mellitus (GDM). 【Methods】 A total of 150 patients with GDM admitted to our hospital from January 2022 to December 2024 were selected and randomly divided into the observation group and the control group at a ratio of 1∶1, with 75 cases in each group. The control group was treated with insulin aspart alone, while the observation group was treated with combined insulin aspart and insulin detemir on the basis of the control group. The clinical efficacy, blood glucose levels [fasting plasma glucose (FPG), 2-hour postprandial blood glucose (2hPG)], islet-related hormone and adipokine levels [C-peptide, visfatin (VF), leptin (LP), adiponectin], islet cell function indicators [fasting insulin (FINS), homeostasis model assessment of β-cell function (HOMA-β)] and homeostasis model assessment of insulin resistance (HOMA-IR) were compared between the two groups. 【Results】 The total clinical effective rate of the observation group was higher than that of the control group (P<0.05). After treatment, the levels of FPG, 2hPG, VF, LP, FINS and HOMA-IR in the observation group were lower than those in the control group (P<0.05), while the levels of C-peptide, adiponectin and HOMA-β were higher (P<0.05). 【Conclusion】 The combination of insulin aspart and insulin detemir can significantly improve the clinical efficacy, optimize blood glucose status, regulate the levels of islet-related hormones and enhance islet cell function in the treatment of GDM.

Key words： Diabetes, Gestational Insulins Treatment Outcome

Received: 23 October 2025

PACS:

R714.256

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YANG Weixiao
	LIU Xiaohui
	YIN Huanhuan

Cite this article:

YANG Weixiao,LIU Xiaohui,YIN Huanhuan. Clinical Efficacy of Insulin Aspart Combined with Insulin Detemir in the Treatment of Patients with Gestational Diabetes Mellitus[J]. JOURNAL OF CLINICAL RESEARCH, 2026, 43(6): 962-964.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2026.06.023 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2026/V43/I6/962

[1] 杨坤,郭云霞,刘艳会,等. 高压氧联合门冬胰岛素对妊娠期糖尿病孕妇胰岛素抵抗及妊娠结局的影响[J].中华航海医学与高气压医学杂志,2024,31(6):757-760.
[2] 陈海燕,严晓瑞,潘娜娜,等. 不同类型胰岛素治疗妊娠期糖尿病的效果及对妊娠结局的影响[J].川北医学院学报,2024,39(4):555-558.
[3] 熊贤翠,贺译平,李亚妮,等. 精蛋白重组人胰岛素联合门冬胰岛素治疗妊娠期糖尿病的疗效及其对血清和肽素水平、胰岛素抵抗和胰岛β细胞功能的影响[J].检验医学与临床,2025,22(5):596-599.
[4] 肖凌艺,廖丹,罗红梅,等. 门冬胰岛素联合地特胰岛素治疗GDM患者的临床疗效研究[J].湖南师范大学学报(医学版),2024,21(2):93-97.
[5] 纪毅梅,姚慧珍,程燕. 地特胰岛素联合门冬胰岛素对妊娠合并糖尿病患者胰岛功能和妊娠结局的影响[J].中国妇幼保健,2022,37(1):19-23.
[6] 魏小辉,王育璠.2015年国际妇产科联盟(FIGO)妊娠期糖尿病诊疗指南解读[J].中华内分泌代谢杂志,2016,32(11):895-899.
[7] 何文慧,刘风伟,段艳芳,等. 门冬胰岛素联合二甲双胍治疗妊娠期糖尿病临床观察[J].中国药业,2023,32(22):108-111.
[8] 孟玥秀. 门冬胰岛素联合营养和运动干预在妊娠期糖尿病患者中的临床效果分析[J].河北医药,2022,44(11):1650-1653.
[9] 董珊珊,刘循灿,程飞飞,等. 门冬胰岛素注射液联合维生素D对妊娠期糖尿病孕妇的影响[J].成都医学院学报,2025,20(1):98-101.
[10] 袁丽娟,史晓霞,杜会英,等. 门冬胰岛素联合不同疗程双歧杆菌三联活菌肠溶胶囊对妊娠期糖尿病患者胰岛素抵抗、脂代谢及妊娠结局的影响研究[J].中国医院用药评价与分析,2024,24(8):944-947.
[11] 杨莉莉,俞海娜,黄弃疾. 门冬胰岛素在妊娠期糖尿病患者中的应用效果观察及妊娠结局分析[J].中国妇幼保健,2022,37(10):1785-1787.
[12] 沈霞光,王凤英. 门冬胰岛素对妊娠期糖尿病孕妇血糖控制情况血清骨钙素水平及母婴不良结局的影响[J].中国妇幼保健,2022,37(11):1953-1956.
[13] 陈凯,梁微微. 双歧杆菌三联活菌联合门冬胰岛素治疗GDM临床效果[J].中国计划生育学杂志,2025,33(4):810-814.
[14] 严明勤,于晓霞,徐郁. 阿司匹林联合二甲双胍对血糖控制不佳妊娠期糖尿病孕妇子痫前期的预防效果[J].中国药物应用与监测,2025,22(2):289-292.